An apoptosis panel for nonalcoholic steatohepatitis diagnosis.
Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, Schauer PR, Zein NN, Feldstein AE.
J Hepatol 2011;54:1224-1229.
Nonalcoholic fatty liver disease (NAFLD) is a wide-spectrum disease entity from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. After Ludwig et al1 introduced the name of NASH firstly in 1980, the concerns about NASH have been explored intensively. The majority of cryptogenic cirrhosis diagnosed in the past presume the progressed state of NASH. Approximately 90% of abnormal liver function without specific causes such as virus, alcohol, toxic and genetic factor presumes NAFLD.2 For diagnosis of NAFLD, several causes which can induce hepatic steatosis should be excluded such as protein-calorie malnutrition, starvation, total parenteral nutrition, rapid weight loss, amiodarone, methotraxate, valproic acid, glucocorticoid, calcium-channel blocker, tamoxifen, tetracycline, and aspirin.2 Although the prevalence of NAFLD is different among countries and races, about 10-20% of general population may have NAFLD.2
Simple hepatic steatosis is usually thought as a non-progressive condition,3 but about 5% of hepatic steatosis can progress to NASH.4 In contrast to hepatic steatosis, approximately 30% of NASH shows the progression of fibrosis within 5 years;5 about 20% of NASH progresses to cirrhosis during lifetime.6 Once cirrhosis is developed, the risk of complications of cirrhosis is increased such as ascites, variceal bleeding, hepatic encephalopathy and development of hepatocellular carcinoma.7 NASH should be discriminated from simple hepatic steatosis because of the above reasons. Liver biopsy is still gold standard for differentiating between steatosis and NASH. The pathologic findings of NASH are macrovesicular steatosis, lobular inflammation, Mallory bodies, ballooning degeneration, and perisinusoidal/perivenular fibrosis. Using these parameters, Brunt et al8 introduced necroinflammatory grade and fibrosis score system for NASH in 1999. Recently, NASH Clinical Research Network introduced new system in which the degrees of steatosis, lobular inflammation, hepatocyte ballooning and Mallory bodies are scored as NAFLD activity score (NAS).9 NASH can be differentiated from hepatic steatosis with NAS system. However, liver biopsy is an invasive procedure with significant complication like bleeding. Several non-invasive biomarkers for diagnosis of NASH have been investigated recently. Palekar et al10 investigated the model for predicting NASH using 8-epi-PGF2α, TGF-β, hyaluronic acid and adiponectin (sensitivity: 73.7%, specificity: 65.7%, positive predictive value: 68.2%, negative predictive value: 68.2%). Poynard et al11 introduced the model, Steatotest for predicting over 30% steatosis using alanine aminotransferase (ALT), a2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, γ-glutamyl transpeptidase (GGT), cholesterol, triglycerides, glucose, age, gender and body mass index (BMI) (sensitivity: 90%, specificity: 90%, negative predictive value: 93%, positive predictive value: 63%). FibroTest was introduced for predicting advanced fibrosis (F3, F4) using α2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, GGT and ALT (positive predictive value: 73%, negative predictive value: 90%).12 Similarly, NAFLD fibrosis score was investigated for predicting advanced fibrosis using age, hyperglycemia, BMI, platelet count, albumin and aspartate aminotransferase (AST)/ALT ratio (positive predictive value: 82%, negative predictive value: 93%).13 Several inflammatory mediators are increased in NASH compared to simple hepatic steatosis such as tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), CC-chemokine ligand 2 (CCL-2), and hyaluronic acid.14-16
Deregulation of hepatocyte apoptosis is an important mechanism of liver injury and NASH development.17-19 Fas has a critical role in apoptosis pathway as a death receptor member of the TNF receptor family. Expression of this membrane protein is increased in NASH patients.17 Accumulation of free fatty acids in hepatocytes results in up-regulation of Fas in the cell membrane which increases the sensitivity to Fas mediated apoptosis.20 At the level of mitochondria, apoptosis pathway induces permiabilization of the mitochondrial outer membrane and release of multiple protein from the mitochondrial inner membrane space to cytoplasm.21 This results in activation of effector caspases (mainly caspase 3) which will cleave substrates in cytoplasm like cytokeratin 18 (CK-18), the major intermediate filament protein of liver, inducing the specific morphologic change of apoptosis.21 There are several reports showing that the quantification of this caspase generated CK-18 fragments is useful for diagnosis of NASH.22-25
In subject study, they investigated the apoptosis panel for non-invasive diagnosis of NASH using these two biomarkers, serum CK-18 fragments and soluble Fas (sFas). Compared to each single biomarker, the combination of two biomarkers, serum CK-18 fragments and sFas showed significantly higher area under curve (AUC) (0.86 in CK-18, 0.86 in sFas and 0.93 in CK-18 with sFas), sensitivity (88%), and specificity (89%) for diagnosis of NASH. The high AUC in the validation group (0.79) indicates the reproducibility of this apoptosis panel. This apoptosis panel for NASH diagnosis is non-invasive, simple, reproducible and reliable method which is needed in real clinical situation. Not only for diagnosis but also for assessment of treatment response and prognosis, this apoptosis panel with serum CK-18 fragments and sFas could be used after proper researches are done.
In conclusion, this diagnostic apoptosis panel including serum CK-18 fragments and sFas for diagnosis of NASH is useful test in clinical practice for noninvasive diagnosis of NASH as a simple, easy to measure, reproducible and reliable method. Further studies are needed to validate the accuracy of this apoptosis panel for NASH diagnosis in each race and country. We need to investigate whether this apoptosis panel could be used for assessment of treatment response and predicting prognosis of NASH.
AbbreviationsNAFLD
nonalcoholic fatty liver disease
NASH
nonalcoholic steatohepatitis
NAS
NAFLD activity score
ALT
alanine aminotransferase
GGT
γ-glutamyl transpeptidase
BMI
body mass index
AST
aspartate aminotransferase
CK-18
cytokeratin 18
sFas
soluble Fas
AUC
area under curve
LudwigJViggianoTRMcGillDBOhBJNonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease1980554344387382552AnguloPNonalcoholic fatty liver disease20023461221123111961152AdamsLALympJFStSauverJSandersonSOLindorKDFeldsteinAThe natural history of nonalcoholic fatty liver disease: a population-based cohort study200512911312116012941DayCPNatural history of NAFLD: remarkably benign in the absence of cirrhosis200512937537816012969FassioEAlvarezEDomínguezNLandeiraGLongoCNatural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies20044082082615382171EdmisonJMcCulloughAJPathogenesis of non-alcoholic steatohepatitis: human data20071175104ix17544973BugianesiELeoneNVanniEMarchesiniGBrunelloFCarucciPExpanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma200212313414012105842BruntEMJanneyCGDi BisceglieAMNeuschwander-TetriBABaconBRNonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions1999942467247410484010KleinerDEBruntEMVan NattaMBehlingCContosMJCummingsOWDesign and validation of a histological scoring system for nonalcoholic fatty liver disease2005411313132115915461PalekarNANausRLarsonSPWardJHarrisonSAClinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease20062615115616448452PoynardTRatziuVNaveauSThabutDCharlotteFMessousDThe diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis200541016375767RatziuVMassardJCharlotteFMessousDImbert-BismutFBonyhayLDiagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease20066616503961AnguloPHuiJMMarchesiniGBugianesiEGeorgeJFarrellGCThe NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD20074584685417393509HaukelandJWDamåsJKKonopskiZLøbergEMHaalandTGoverudISystemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL22006441167117416618517SuzukiAAnguloPLympJLiDSatomuraSLindorKHyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease20052577978615998429AbiruSMigitaKMaedaYDaikokuMItoMOhataKSerum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis200626394516420507FeldsteinAECanbayAAnguloPTaniaiMBurgartLJLindorKDHepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis200312543744312891546WieckowskaAZeinNNYerianLMLopezARMcCulloughAJFeldsteinAEIn vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease200644273316799979FeldsteinAEGoresGJApoptosis in alcoholic and nonalcoholic steatohepatitis2005103093309915970563FeldsteinAECanbayAGuicciardiMEHiguchiHBronkSFGoresGJDiet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice20033997898314642615MalhiHGoresGJCellular and molecular mechanisms of liver injury20081341641165418471544FeldsteinAEWieckowskaALopezARLiuYCZeinNNMcCulloughAJCytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study2009501072107819585618DiabDLYerianLSchauerPKashyapSRLopezRHazenSLCytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients200861249125418995215YounossiZMJarrarMNugentCRandhawaMAfendyMStepanovaMA novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)2008181430143718500507MalikRChangMBhaskarKNasserICurryMSchuppanDThe clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease20092456456819378390